多瑞医药 (301075.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(多瑞医药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2025年第三季度2025年第二季度2025年第一季度2024年第四季度2024年第三季度2024年第二季度2024年第一季度2023年第四季度2023年第三季度2023年第二季度2023年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 会员可见会员可见会员可见会员可见50,139,668.3171,923,092.2578,457,398.2688,042,592.2375,863,073.7892,308,527.6778,085,173.39
 营业收入(元) 会员可见会员可见会员可见会员可见50,139,668.3171,923,092.2578,457,398.2688,042,592.2375,863,073.7892,308,527.6778,085,173.39
二、营业总成本(元) 会员可见会员可见会员可见会员可见70,978,408.2577,854,053.2584,406,149.3191,004,473.3276,539,171.6881,077,622.5681,960,671.26
 营业成本(元) 会员可见会员可见会员可见会员可见26,966,573.1044,350,501.4747,485,816.2933,340,564.5822,838,010.1221,413,407.3727,537,913.38
 研发费用(元) 会员可见会员可见会员可见会员可见11,573,242.153,395,495.533,017,966.199,242,262.302,350,535.185,563,322.426,839,149.50
 营业税金及附加(元) 会员可见会员可见会员可见会员可见376,409.26653,844.36397,392.351,106,515.41974,913.271,096,660.92695,747.17
 销售费用(元) 会员可见会员可见会员可见会员可见20,196,317.0120,341,731.3722,638,749.5739,003,345.5039,481,491.2544,313,070.3139,048,134.19
 管理费用(元) 会员可见会员可见会员可见会员可见11,374,135.259,062,131.8810,715,882.749,436,799.3711,885,153.659,803,836.059,158,260.28
 财务费用(元) 会员可见会员可见会员可见会员可见491,731.4850,348.64150,342.17-1,125,013.84-990,931.79-1,112,674.51-1,318,533.26
  其中:利息费用(元) -会员可见会员可见会员可见1,505,791.641,353,861.051,412,640.46787,868.66823,971.88675,224.71825,466.72
  其中:利息收入(元) -会员可见会员可见会员可见1,027,815.821,375,117.101,275,825.301,912,761.152,605,980.921,043,564.222,152,976.10
 资产减值损失(元) 会员可见会员可见会员可见会员可见-44,094.08501,593.43-2,451.55-287,199.31-174,352.44--
 信用减值损失(元) 会员可见会员可见会员可见会员可见-663,544.25339,539.69-81,557.242,932,301.78-53,622.67-1,903,457.65-10,594.27
三、其他经营收益
 加:公允价值变动收益(元) -会员可见会员可见会员可见279,906.95------
 加:投资收益(元) 会员可见会员可见会员可见会员可见2,223,357.131,462,206.812,467,690.071,561,283.582,716,953.00512,371.64852,902.18
  其中:对联营企业和合营企业的投资收益(元) -会员可见会员可见会员可见1,641,425.37409,847.731,253,503.821,319,066.751,621,266.50-243,628.36140,118.11
 其他收益(元) 会员可见会员可见会员可见会员可见121,659.5747,317.9662,078.72678,106.263,577,110.937,850,198.37669,131.63
四、营业利润(元) 会员可见会员可见会员可见会员可见-18,876,171.61-3,350,969.43-3,502,991.052,049,032.005,412,458.9217,089,744.95-2,364,058.33
 加:营业外收入(元) 会员可见会员可见-会员可见-271,006.57320,395.051,767.29-126,019.9689,178.25626,323.9036,263.50
 减:营业外支出(元) 会员可见会员可见会员可见会员可见396,444.99103,434.943,964.5095,145.0499,665.96365,404.233,879.36
五、利润总额(元) 会员可见会员可见会员可见会员可见-19,543,623.17-3,134,009.32-3,505,188.261,827,867.005,401,971.2117,350,664.62-2,331,674.19
 减:所得税费用(元) 会员可见会员可见会员可见会员可见-779,920.191,085,676.9869,759.282,390,109.041,155,490.171,422,470.33189,037.00
六、净利润(元) 会员可见会员可见会员可见会员可见-18,763,702.98-4,219,686.30-3,574,947.54-562,242.044,246,481.0415,928,194.29-2,520,711.19
(一)按经营持续性分类
  持续经营净利润(元) 会员可见会员可见会员可见会员可见-18,763,702.98-4,219,686.30-3,574,947.54-562,242.044,246,481.0415,928,194.29-2,520,711.19
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 会员可见会员可见会员可见会员可见-13,802,326.80-739,135.26-2,537,276.14-460,053.694,944,453.1416,783,577.72-2,417,228.83
  少数股东损益(元) 会员可见会员可见会员可见会员可见-4,961,376.18-3,480,551.04-1,037,671.40-102,188.35-697,972.10-855,383.43-103,482.36
 扣除非经常性损益后的净利润(元) 会员可见会员可见会员可见会员可见-14,076,214.11-1,860,580.78-3,749,287.34-649,562.45886,273.008,711,686.74-3,697,550.37
七、每股收益
 一、基本每股收益(元) 会员可见会员可见会员可见会员可见-0.17-0.01-0.03-0.060.21-0.03
 二、稀释每股收益(元) 会员可见会员可见会员可见会员可见-0.17-0.01-0.03-0.060.21-0.03
八、其他综合收益(元) --------5,929,462.68--7,901,385.00
 归属于母公司股东的其他综合收益(元) --------5,929,462.68--7,901,385.00
九、综合收益总额(元) 会员可见会员可见会员可见会员可见-18,763,702.98-4,219,686.30-3,574,947.54-6,491,704.724,246,481.0415,928,194.295,380,673.81
 归属于母公司所有者的综合收益总额(元) 会员可见会员可见会员可见会员可见-13,802,326.80-739,135.26-2,537,276.14-6,389,516.374,944,453.1416,783,577.725,484,156.17
 归属于少数股东的综合收益总额(元) 会员可见会员可见会员可见会员可见-4,961,376.18-3,480,551.04-1,037,671.40-102,188.35-697,972.10-855,383.43-103,482.36
公告日期 2025-10-24 00:00:002025-08-27 00:00:002025-04-25 00:00:002025-04-18 00:00:002024-10-25 00:00:002024-08-27 00:00:002024-04-25 00:00:002024-04-18 00:00:002023-10-27 00:00:002023-08-25 00:00:002023-04-25 00:00:00
审计意见(境内) 标准无保留意见标准无保留意见

前瞻产业研究院